Pay in 4 interest-free payments of $7.35 Learn more
Ships within 48 hours · Estimated delivery Nov 5 - Nov 10
Key Morningstar Metrics for Novo Nordisk Fair value estimate: $71 Morningstar Rating: Morningstar Economic Moat Rating: Wide Morningstar Uncertainty Rating: High Economic Moat Novos intangible assets in diabetes and related cardiometabolic diseases like obesity give the firm a wide economic moat that will shield profitability for the long run
Supports Healthy, Maintainable Weight Loss A key benefit of GLP-1 agonists is their ability to help with weight loss
You dont have to get approval from Kaiser Permanente first
Anti-obesity drug therapy can be offered as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial body mass index (BMI) of 30 kg/m 2 or 2730 kg/m 2 in the presence of at least one weight-related comorbidity, e.g., dysglycemia, hypertension, dyslipidemia, or obstructive sleep apnea
Bakermans AJ, et al
They talk about this a bit, but make the (odd, to me, at least) choice to compare the 104-week SELECT (cardiovascular) trial to the 68-week STEP 1 (weight loss) trial, rather than the 104-week STEP 5 (weight loss) Trial
US$ 27.60
US$ 25.23
US$ 27.85
US$ 23.03
US$ 28.31
